$288 price target - currently at $140 - takes market cap to $15 billion plus, on "best in industry gene therapy/CAR T pipeline" including bb2121.
Assuming this is Flynn related, how does it not positively impact his opinion on Celgene? Another mystery wrapped in an enigma - like current Celgene PPS performance?
Celgene's pipe line is not given credit, and yet, its partnered pipeline candidates do relative to the partnered company - along with the previous UBS XLRN post.
Frustrating to watch the impact of the doubting Missouri "show me" analysts on Celgene, when they apparently like the partnered products promise.
Hopefully, this too will pass. Waiting with baited breath. Headed on an annual trip in thirty days rooting for corked bottles.
PS - yesterday's opt-out decision also demonstrates Celgene's discipline on going with high priority candidates.
